^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRGN-3005

    i
    Associations
    News

    Trials

    Company:
    Precigen
    Drug class:
    IL-15-targeted CAR-T immunotherapy, MUC16-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527)
    Phase 1
    Precigen, Inc
    Recruiting
    Last update posted :
    11/13/2023
    Initiation :
    04/30/2019
    Primary completion :
    12/15/2024
    Completion :
    11/15/2028
    BRCA
    |
    BRCA mutation
    |
    PRGN-3005